Download PDF
Dtsch Med Wochenschr 2018; 143(02): 89-100
DOI: 10.1055/s-0043-106563
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Nierenbeteiligung bei Kollagenosen

Renal Involvement in Connective Tissue Diseases
Stefan Markus Weiner
Further Information

Publication History

Publication Date:
22 January 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Renal involvement is common and heterogenous in connective tissue diseases and has a main influence on prognosis and mortality. In systemic lupus erythematosus proliferative glomerulonephritis is the most common manifestation, while in primary Sjogren’s syndrome interstitial nephritis with tubular dysfunction is the predominant pathological feature. In systemic sclerosis the most serious renal manifestation is scleroderma renal crisis characterized by abrupt onset of hypertension and acute kidney injury associated with an increase in plasma renin activity. Risk factors for scleroderma renal crisis are diffuse cutaneous involvement, treatment with corticosteroids > 15 mg prednisolone/day and treatment with calcineurin inhibitors.

Regular measurement of urine sediment, proteinuria-to-urine creatinine ratio, tubular proteinuria, measurement of plasma creatinine, and office as well as home blood pressure monitoring are strongly recommended. Diagnostic kidney biopsy is essential in differentiating the different types of lupus nephritis and renal involvement in sjogren’s syndrome.

The optimal treatment of lupus nephritis varies with the classification of the morphological findings present on renal biopsy. The treatment of interstitial nephritis in sjogren’s syndrome consists of immunosuppression e. g. corticosteroids. Renal tubular acidosis should be corrected by sodium alkali and potassium alkali. Angiotensin-converting enzyme inhibitors play a major role in the treatment of scleroderma renal crisis, they should be continued also in patients progressing to end-stage renal disease.

Bei Kollagenosen sind häufig die Nieren mitbeteiligt – mit ungünstigem Einfluss auf die Prognose, insbesondere bei progredienter Niereninsuffizienz. Eine Nierenbiopsie ist wegen der Heterogenität der Nierenbeteiligung und der unterschiedlichen Therapieverfahren unabdingbar. Der folgende Beitrag gibt einen Überblick über die Formen und die Diagnostik der Nierenbeteiligung bei Kollagenosen und zeigt aktuelle Therapieempfehlungen.

Schlüsselwörter

Nierenbeteiligung - Kollagenosen - Lupusnephritis - interstitielle Nephritis - skleroderme renale Krise

Key words

renal involvement - connective tissue diseases - lupus nephritis - interstitial nephritis - scleroderma renal crisis
 

  • Literatur

  • 1 Petri M, Orbai AM, Alarcón GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686
    CrossrefPubMedGoogle Scholar
  • 2 Weening JJ, D’Agati VD, Schwartz MM. et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
    CrossrefPubMedGoogle Scholar
  • 3 Chen S, Tang Z, Zhang Y. et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol 2013; 38: 445-452
    CrossrefPubMedGoogle Scholar
  • 4 Bienaimé F, Legendre C, Terzi F. et al. Antiphospholipid syndrome and kidney disease. Kidney Int 2017; 91: 34-44
    CrossrefPubMedGoogle Scholar
  • 5 Dall’Era M, Cisternas MG, Smilek DE. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305-1313
    CrossrefPubMedGoogle Scholar
  • 6 Bertsias GK, Tektonidou M, Amoura Z. et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782
    CrossrefPubMedGoogle Scholar
  • 7 KDIGO. KDIGO guidelines, Chapter 12: Lupus nephritis. Kidney Int 2012; 2: 221-232
    CrossrefPubMedGoogle Scholar
  • 8 Houssiau FA, Vasconcelos C, D’Cruz D. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
    CrossrefPubMedGoogle Scholar
  • 9 Tamirou F, Husson SN, Gruson D. et al. Brief report: The Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol 2017; 69: 1267-1271
    CrossrefPubMedGoogle Scholar
  • 10 Daleboudt GM, Reinders ME, den HartighJ. et al. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 2013; 22: 171-179
    CrossrefPubMedGoogle Scholar
  • 11 Liu Z, Zhang H, Liu Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162: 18-26
    CrossrefPubMedGoogle Scholar
  • 12 Rovin BH, Furie R, Latinis K. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226
    CrossrefPubMedGoogle Scholar
  • 13 Dooley MA, Jayne D, Ginzler EM. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
    CrossrefPubMedGoogle Scholar
  • 14 Tamirou F, D’Cruz D, Sangle S. et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016; 75: 526-531
    CrossrefPubMedGoogle Scholar
  • 15 Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2154-2160
    CrossrefPubMedGoogle Scholar
  • 16 Shiboski CH, Shiboski SC, Seror R. et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9-16
    CrossrefPubMedGoogle Scholar
  • 17 Jasiek M, Karras A, Le GuernV. et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome. Rheumatology (Oxford) 2017; 56: 362-370
    PubMedGoogle Scholar
  • 18 Evans R, Zdebik A, Ciurtin C. et al. Renal involvement in primary Sjögren’s syndrome. Rheumatology (Oxford) 2015; 54: 1541-1548
    CrossrefPubMedGoogle Scholar
  • 19 Goules AV, Tatouli IP, Moutsopoulos HM. et al. Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65: 2945-2953
    CrossrefPubMedGoogle Scholar
  • 20 Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37: 1380-1385
    CrossrefPubMedGoogle Scholar
  • 21 Gheitasi H, Kostov B, Solans R. et al. How are we treating our systemic patients with primary Sjögren syndrome?. Analysis of 1120 patients. Int Immunopharmacol 2015; 27: 194-199
    PubMedGoogle Scholar
  • 22 Terrier B, Krastinova E, Marie I. et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119: 5996-6004
    CrossrefPubMedGoogle Scholar
  • 23 van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747
    CrossrefPubMedGoogle Scholar
  • 24 Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 2012; 24: 669-676
    CrossrefPubMedGoogle Scholar
  • 25 Shanmugam VK, Steen VD. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010; 2010: pii: 538589
    PubMedGoogle Scholar
  • 26 Hudson M, Baron M, Tatibouet S. et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014; 43: 666-672
    CrossrefPubMedGoogle Scholar
  • 27 Nguyen B, Assassi S, Arnett FC. et al. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37: 1068
    CrossrefPubMedGoogle Scholar
  • 28 Penn H, Howie AJ, Kingdon EJ. et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-494
    CrossrefPubMedGoogle Scholar
  • 29 Montanelli G, Beretta L, Santaniello A. et al. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013; 31: 135-139
    PubMedGoogle Scholar
  • 30 Lynch BM, Stern EP, Ong V. et al. UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 2016; 34 (100) 106-109
    PubMedGoogle Scholar
  • 31 Cozzi F, Marson P, Cardarelli S. et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 2012; 27: 4398-4403
    CrossrefPubMedGoogle Scholar
  • 32 Penn H, Quillinan N, Khan K. et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013; 106: 839-848
    CrossrefPubMedGoogle Scholar
  • 33 Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-603
    CrossrefPubMedGoogle Scholar
  • 34 Siva B, McDonald SP, Hawley CM. et al. End-stage kidney disease due to scleroderma--outcomes in 127 consecutive ANZDATA registry cases. Nephrol Dial Transplant 2011; 26: 3165-3171
    CrossrefPubMedGoogle Scholar
  • 35 Bertrand D, Dehay J, Ott J. et al. Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant Int 2017; 30: 256-265
    CrossrefPubMedGoogle Scholar
  • 36 Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013; 11: 95
    CrossrefPubMedGoogle Scholar